Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma
Copyright © 2021 Lim, Cavanagh, Hicks, McLean, Goh, Webb and Rischin..
Non-melanoma skin cancers are one of the most common cancers diagnosed worldwide, with the highest incidence in Australia and New Zealand. Systemic treatment of locally advanced and metastatic cutaneous squamous cell carcinomas has been revolutionized by immune checkpoint inhibition with PD-1 blockade. We highlight treatment issues distinct to the management of the disease including expansion of the traditional concept of pseudoprogression and describe delayed responses after immune-specific response criteria confirmed progressive disease with and without clinical deterioration. We term this phenomenon "delayed response after confirmed progression (DR)". We also discuss the common development of second primary tumors, heterogeneous disease responses, and expanding clinical boundaries for immunotherapy use.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Frontiers in oncology - 11(2021) vom: 27., Seite 656611 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lim, Annette M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cutaneous squamous carcinoma |
|---|
| Anmerkungen: |
Date Revised 04.05.2021 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fonc.2021.656611 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324901674 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324901674 | ||
| 003 | DE-627 | ||
| 005 | 20231226202949.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fonc.2021.656611 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1082.xml |
| 035 | |a (DE-627)NLM324901674 | ||
| 035 | |a (NLM)33937066 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lim, Annette M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.05.2021 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2021 Lim, Cavanagh, Hicks, McLean, Goh, Webb and Rischin. | ||
| 520 | |a Non-melanoma skin cancers are one of the most common cancers diagnosed worldwide, with the highest incidence in Australia and New Zealand. Systemic treatment of locally advanced and metastatic cutaneous squamous cell carcinomas has been revolutionized by immune checkpoint inhibition with PD-1 blockade. We highlight treatment issues distinct to the management of the disease including expansion of the traditional concept of pseudoprogression and describe delayed responses after immune-specific response criteria confirmed progressive disease with and without clinical deterioration. We term this phenomenon "delayed response after confirmed progression (DR)". We also discuss the common development of second primary tumors, heterogeneous disease responses, and expanding clinical boundaries for immunotherapy use | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a PD-1 inhibition | |
| 650 | 4 | |a cutaneous squamous carcinoma | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a pseudoprogression | |
| 650 | 4 | |a second primary tumors (SPTs) | |
| 700 | 1 | |a Cavanagh, Karda |e verfasserin |4 aut | |
| 700 | 1 | |a Hicks, Rodney J |e verfasserin |4 aut | |
| 700 | 1 | |a McLean, Luke |e verfasserin |4 aut | |
| 700 | 1 | |a Goh, Michelle S |e verfasserin |4 aut | |
| 700 | 1 | |a Webb, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Rischin, Danny |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in oncology |d 2011 |g 11(2021) vom: 27., Seite 656611 |w (DE-627)NLM218189583 |x 2234-943X |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g day:27 |g pages:656611 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fonc.2021.656611 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |b 27 |h 656611 | ||